Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Clin Cancer Res
    September 2021
  1. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
    Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
    >> Share

    August 2021
  2. SZTUPINSZKI Z, Diossy M, Borcsok J, Prosz A, et al
    Comparative Assessment of Diagnostic Homologous Recombination Deficiency associated mutational signatures in ovarian cancer.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-0981.
    >> Share

  3. KAMAT AA, Fletcher M, Gruman LM, Mueller P, et al
    Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
    Clin Cancer Res. 2021;27:4455.
    >> Share

    July 2021
  4. THAKER PH, Bradley WH, Leath CA, Gunderson Jackson C, et al
    GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0360.
    >> Share

    May 2021
  5. KANDIMALLA R, Wang W, Yu F, Zhou N, et al
    OCaMIR - A noninvasive, diagnostic signature for early stage ovarian cancer: a multi-cohort retrospective and prospective study.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0267.
    >> Share

  6. MIAO YR, Thakkar KN, Qian J, Kariolis MS, et al
    Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-0482.
    >> Share

  7. LAUMONT CM, Wouters MCA, Smazynski J, Gierc NS, et al
    Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer.
    Clin Cancer Res. 2021 May 7. pii: 1078-0432.CCR-20-4394.
    >> Share

    March 2021
  8. THIBODEAUX S, Barnett B, Pandeswara S, Wall S, et al
    Interferon-alpha augments clinical efficacy of regulatory T cell depletion with denileukin diftitox in ovarian cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4594.
    >> Share

  9. KAZMI F, Nicum S, Roux RL, Spiers L, et al
    A Phase IB open-label, dose-escalation study of NUC1031 in combination with carboplatin for recurrent ovarian cancer.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4403.
    >> Share

    February 2021
  10. LI N, Bu H, Liu J, Zhu J, et al
    An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
    >> Share

    December 2020
  11. PARACCHINI L, Beltrame L, Grassi T, Inglesi A, et al
    Genome-wide copy number alterations in circulating tumor DNA as a novel biomarker in high grade serous ovarian cancer patients.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-3345.
    >> Share

    September 2020
  12. ISHAK CA, De Carvalho DD
    DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-3331.
    >> Share

  13. YANG H, Mao W, Rodriguez-Aguayo C, Mangala LS, et al
    Correction: Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
    Clin Cancer Res. 2020;26:5050.
    >> Share

  14. JIN ZH, Tsuji AB, Degardin M, Sugyo A, et al
    Radiotheranostic Agent (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1205.
    >> Share

  15. JORDAN K, Sikora MJ, Slansky JE, Minic A, et al
    The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1762.
    >> Share

    August 2020
  16. MCMULLEN M, Karakasis K, Oza AM
    Moving Beyond BRCA - Incorporating Molecular Assays into Ovarian Cancer trials.
    Clin Cancer Res. 2020 Aug 14. pii: 1078-0432.CCR-20-2429.
    >> Share

    July 2020
  17. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    >> Share

  18. OZA AM, Estevez-Diz MDP, Grischke EM, Hall M, et al
    A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.
    Clin Cancer Res. 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
    >> Share

    June 2020
  19. MAY T, Oza AM
    Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer.
    Clin Cancer Res. 2020 Jun 29. pii: 1078-0432.CCR-20-1376.
    >> Share

    May 2020
  20. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    >> Share

  21. JI JX, Cochrane DR, Tessier-Cloutier B, Chen SY, et al
    Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.
    Clin Cancer Res. 2020 May 14. pii: 1078-0432.CCR-19-1905.
    >> Share

  22. LAMPERT EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    Clin Cancer Res. 2020 May 12. pii: 1078-0432.CCR-20-0056.
    >> Share

    April 2020
  23. LI J, Pan C, Boese AC, Kang J, et al
    DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-3790.
    >> Share

    March 2020
  24. YOU B, Robelin P, Tod M, Louvet C, et al
    CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
    Clin Cancer Res. 2020 Mar 24. pii: 1078-0432.CCR-20-0054.
    >> Share

    February 2020
  25. HARRIS RS, Serebrenik AA, Argyris P, Jarvis MC, et al
    The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-2786.
    >> Share

    January 2020
  26. ALVAREZ SECORD A, Bell Burdett K, Owzar K, Tritchler D, et al
    Predictive blood-based biomarkers in epithelial ovarian cancer patients treated with carboplatin and paclitaxel with or without bevacizumab: Results from GOG-0218.
    Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0226.
    >> Share

    December 2019
  27. LI F, Zhang Z, Cai J, Chen X, et al
    Primary preclinical and clinical Evaluation of 68Ga-DOTA-TMVP1 as a novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer.
    Clin Cancer Res. 2019 Dec 16. pii: 1078-0432.CCR-19-1845.
    >> Share

  28. OZA AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, et al
    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-1638.
    >> Share

    October 2019
  29. HANDLEY KF, Sood AK
    A solution to the dilution: The role for biomarkers in advanced ovarian cancer.
    Clin Cancer Res. 2019 Oct 31. pii: 1078-0432.CCR-19-3072.
    >> Share

  30. SOLIMAN PT, Westin SN, Iglesias DA, Fellman BM, et al
    Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study.
    Clin Cancer Res. 2019 Oct 18. pii: 1078-0432.CCR-19-0471.
    >> Share

  31. MCCLOSKEY CW, Cook DP, Kelly BS, Azzi F, et al
    Metformin abrogates age-associated ovarian fibrosis.
    Clin Cancer Res. 2019 Oct 9. pii: 1078-0432.CCR-19-0603.
    >> Share

    September 2019
  32. SHEE K, Wells JD, Ung M, Hampsch RA, et al
    A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
    >> Share

  33. GERBER DE, Infante JR, Gordon MS, Goldberg SB, et al
    Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-18-3965.
    >> Share

  34. HEITZ F, Kommoss S, Tourani R, Grandelis A, et al
    Dilution of molecular-pathologic gene signatures by medically associated factors might prevent prediction of resection status after debulking surgery in patients with advanced ovarian cancer.
    Clin Cancer Res. 2019 Sep 16. pii: 1078-0432.CCR-19-1741.
    >> Share

  35. BONILLA L, Oza AM
    Targeting TGFbeta Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?
    Clin Cancer Res. 2019;25:5432-5434.
    >> Share

  36. MAITLAND ML, O'Cearbhaill RE, Gobburu J
    Cancer Clinical Investigators Should Converge with Pharmacometricians.
    Clin Cancer Res. 2019;25:5182-5184.
    >> Share

    August 2019
  37. PARMAR K, Kochupurakkal BS, Lazaro JB, Wang ZC, et al
    The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP inhibition.
    Clin Cancer Res. 2019 Aug 13. pii: 1078-0432.CCR-19-0448.
    >> Share

  38. YANG H, Shu Z, Jiang Y, Mao W, et al
    6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
    Clin Cancer Res. 2019 Aug 7. pii: 1078-0432.CCR-18-3448.
    >> Share

    July 2019
  39. ISHAK CA, Lheureux S, De Carvalho DD
    DNA methylation as a robust classifier of epithelial ovarian cancer.
    Clin Cancer Res. 2019 Jul 23. pii: 1078-0432.CCR-19-1797.
    >> Share

  40. YEUNG TL, Leung CS, Yip KP, Sheng J, et al
    Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer.
    Clin Cancer Res. 2019 Jul 22. pii: 1078-0432.CCR-19-0187.
    >> Share

  41. TINKER AV, Hirte HW, Provencher DM, Butler MO, et al
    Dose-ranging and cohort-expansion study of monalizumab(IPH2201) in advanced gynecologic malignancies:A trial of the Canadian Cancer Trials Group (CCTG):IND221.
    Clin Cancer Res. 2019 Jul 15. pii: 1078-0432.CCR-19-0298.
    >> Share

  42. LI Z, Zhou W, Zhang Y, Sun W, et al
    ERK regulates HIF-1alpha-mediated platinum resistance by directly targeting PHD2 in ovarian cancer.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-18-4145.
    >> Share

    May 2019
  43. BODELON C, Killian JK, Sampson JN, Anderson WF, et al
    Molecular classification of epithelial ovarian cancer based on methylation profiling: evidence for survival heterogeneity.
    Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-3720.
    >> Share

  44. FUCIKOVA J, Rakova J, Hensler M, Kasikova L, et al
    TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer.
    Clin Cancer Res. 2019 May 10. pii: 1078-0432.CCR-18-4175.
    >> Share

  45. TAO JJ, Cangemi NA, Makker V, Cadoo K, et al
    First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
    Clin Cancer Res. 2019 May 8. pii: 1078-0432.CCR-19-1065.
    >> Share

    April 2019
  46. POSTOVIT LM, Dieters-Castator DZ, Rambau PF, Kelemen LE, et al
    Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3818.
    >> Share

  47. KAWAKAMI E, Tabata J, Yanaihara N, Ishikawa T, et al
    Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
    Clin Cancer Res. 2019 Apr 11. pii: 1078-0432.CCR-18-3378.
    >> Share

  48. TAKENAKA M, Kobel M, Garsed DW, Fereday S, et al
    Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma is Not Associated with Pathological Misclassification of Tumor Histotype.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-18-3691.
    >> Share

  49. COLOMBAN O, Tod M, Leary A, Ray-Coquard I, et al
    Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
    Clin Cancer Res. 2019 Apr 1. pii: 1078-0432.CCR-18-3335.
    >> Share

    March 2019
  50. BYKOV Y, Zamarin D
    Virus, Vessel, Victory: A Novel Approach to Tumor Killing.
    Clin Cancer Res. 2019;25:1446-1448.
    >> Share

    January 2019
  51. GREENWOOD HE, McCormick PN, Gendron T, Glaser M, et al
    Measurement of tumor antioxidant capacity and prediction of chemotherapy resistance in preclinical models of ovarian cancer by positron emission tomography.
    Clin Cancer Res. 2019 Jan 16. pii: 1078-0432.CCR-18-3423.
    >> Share

    December 2018
  52. BLAGDEN SP, Hamilton AL, Mileshkin L, Wong S, et al
    Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-2277.
    >> Share

    October 2018
  53. WU G, Cao L, Zhu J, Tan Z, et al
    Loss of RBMS3 Confers Platinum-resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/beta-catenin/CBP signaling.
    Clin Cancer Res. 2018 Oct 2. pii: 1078-0432.CCR-18-2554.
    >> Share

    September 2018
  54. MATUSZEWSKA K, Santry LA, Van Vloten JP, Au Yeung A, et al
    Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in Advanced Stage Ovarian Cancer.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-0220.
    >> Share

    August 2018
  55. PISANIC TR, Cope L, Lin SF, Yen TT, et al
    Methylomic analysis of ovarian cancers identifies tumor-specific alterations readily detectable in early precursor lesions.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1199.
    >> Share

  56. LHEUREUX S, Tinker AV, Clarke BA, Ghatage P, et al
    A clinical and molecular Phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): A study of the Princess Margaret Phase II Consortium.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1244.
    >> Share

    July 2018
  57. TOKER A, Nguyen LT, Stone SC, Yang C, et al
    Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-18-0554.
    >> Share

  58. MCNEISH IA
    Neoantigens in ovarian cancer: embarrassment of riches or needles in a haystack?
    Clin Cancer Res. 2018 Jul 6. pii: 1078-0432.CCR-18-1731.
    >> Share

  59. BLYUSS O, Burnell M, Ryan A, Gentry-Maharaj A, et al
    Comparison of longitudinal CA125 algorithms as a first line screen for ovarian cancer in the general population.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0208.
    >> Share

  60. YANG H, Mao W, Rodriguez-Aguayo C, Mangala LS, et al
    Paclitaxel Sensitivity of Ovarian Cancer can be enhanced by knocking down Pairs of Kinases that regulate MAP4 Phosphorylation and Microtubule Stability.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0504.
    >> Share

  61. CHEN GM, Kannan L, Geistlinger L, Kofia V, et al
    Consensus on Molecular Subtypes of High-grade Serous Ovarian Carcinoma.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0784.
    >> Share

    June 2018
  62. SIMPKINS F, Jang K, Yoon H, Hew K, et al
    Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells.
    Clin Cancer Res. 2018 Jun 29. pii: 1078-0432.CCR-17-3697.
    >> Share

  63. KONSTANTINOPOULOS PA, Matulonis UA
    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.
    Clin Cancer Res. 2018 Jun 5. pii: 1078-0432.CCR-18-1314.
    >> Share

  64. TUMIATI M, Hietanen S, Hynninen J, Pietila E, et al
    A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-17-3770.
    >> Share

    May 2018
  65. DENIGER DC, Pasetto A, Robbins PF, Gartner JJ, et al
    T-cell responses to TP53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers.
    Clin Cancer Res. 2018 May 31. pii: 1078-0432.CCR-18-0573.
    >> Share

  66. GRISHAM R, Moore KN, Gordon MS, Harb W, et al
    Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0494.
    >> Share

  67. UUSI-KERTTULA H, Davies JA, Thompson J, Wongthida P, et al
    Ad5NULL-A20 - a tropism-modified, alphavbeta6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies.
    Clin Cancer Res. 2018 May 24. pii: 1078-0432.CCR-18-1089.
    >> Share

  68. MATSUDA T, Leisegang M, Park JH, Ren L, et al
    Induction of Neoantigen-specific Cytotoxic T Cells and Construction of T-cell Receptor-engineered T cells for Ovarian Cancer.
    Clin Cancer Res. 2018 May 2. pii: 1078-0432.CCR-18-0142.
    >> Share

    April 2018
  69. CAUMANNS JJ, Berns K, Wisman GBA, Fehrmann RSN, et al
    Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.
    Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3060.
    >> Share

  70. DI LJ, Hao D, Liu J, Chen M, et al
    Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemo-sensitivity.
    Clin Cancer Res. 2018 Apr 16. pii: 1078-0432.CCR-17-3862.
    >> Share

  71. BELUR NAGARAJ A, Kovalenko O, Avelar RA, Joseph P, et al
    Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer.
    Clin Cancer Res. 2018 Apr 13. pii: 1078-0432.CCR-17-2885.
    >> Share

  72. ISON G, Howie LJ, Amiri-Kordestani L, Zhang L, et al
    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.
    Clin Cancer Res. 2018 Apr 12. pii: 1078-0432.CCR-18-0042.
    >> Share

  73. PULLIAM N, Fang F, Ozes AR, Tang J, et al
    An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0204.
    >> Share

    March 2018
  74. KALLI KR, Block MS, Kasi PM, Erskine CL, et al
    Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients.
    Clin Cancer Res. 2018 Mar 15. pii: 1078-0432.CCR-17-2499.
    >> Share

  75. MATEI D, Ghamande S, Roman LD, Alvarez Secord A, et al
    A Phase 1 Clinical Trial of Guadecitabine and Carboplatin In Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic And Pharmacodynamic Analyses.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-3055.
    >> Share

    February 2018
  76. HUANG YF, Wu YH, Cheng WF, Peng SL, et al
    Vitamin D-Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-2943.
    >> Share

  77. LANG JD, Hendricks WPD, Orlando KA, Yin H, et al
    Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
    Clin Cancer Res. 2018 Feb 9. pii: 1078-0432.CCR-17-1928.
    >> Share

    January 2018
  78. BELLONE S, Buza N, Choi J, Zammataro L, et al
    Exceptional response to pembrolizumab in a metastatic, chemotherapy/radiation resistant ovarian cancer patient harboring a CD274/PD-L1-genetic rearrangement.
    Clin Cancer Res. 2018 Jan 19. pii: 1078-0432.CCR-17-1805.
    >> Share

  79. HARDWICK NR, Frankel P, Ruel C, Kilpatrick J, et al
    p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2709.
    >> Share

    December 2017
  80. TUCKER DW, Getchell CR, McCarthy ET, Ohman AW, et al
    Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1958.
    >> Share

    November 2017
  81. PENG G, Mills GB
    Surviving ovarian cancer: an affair between defective DNA repair and RB1.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-3022.
    >> Share

  82. NORQUIST BM, Brady MF, Harrell MI, Walsh T, et al
    Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-1327.
    >> Share

    October 2017
  83. LABIDI-GALY SI, Olivier T, Rodrigues M, Ferraioli D, et al
    Location of mutation in BRCA2 gene and survival in patients with ovarian cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.2136.2017.
    >> Share

  84. GARSED DW, Alsop K, Fereday S, Emmanuel C, et al
    Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017.
    >> Share

  85. KREUZINGER C, Geroldinger A, Smeets D, Braicu EI, et al
    A complex network of tumor microenvironment in human high grade serous ovarian cancer.
    Clin Cancer Res. 2017 Oct 2. pii: clincanres.1159.2017.
    >> Share

    September 2017
  86. COOKE SL, Ennis D, Evers L, Dowson S, et al
    The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.1789.2017.
    >> Share

  87. HAO D, Li J, Jia S, Meng Y, et al
    Integrated analysis reveals tubal and ovarian originated serous ovarian cancer and predicts differential therapeutic responses.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0638.2017.
    >> Share

    August 2017
  88. RAGHAVAN S, Mehta P, Ward MW, Bregenzer ME, et al
    Personalized Medicine Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0133.2017.
    >> Share

  89. LIU J, Agopiantz M, Poupon J, Wu Z, et al
    Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0861.2017.
    >> Share

  90. CORNELISON R, Dobbin ZC, Katre AA, Jeong DH, et al
    TARGETING RNA-POLYMERASE I IN BOTH CHEMOSENSITIVE AND CHEMORESISTANT POPULATIONS IN EPITHELIAL OVARIAN CANCER.
    Clin Cancer Res. 2017 Aug 4. pii: clincanres.0282.2017.
    >> Share

  91. WEIGELT B, Comino-Mendez I, de Bruijn I, Tian L, et al
    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0544.2017.
    >> Share

    July 2017
  92. BALASUBRAMANIAM S, Beaver JA, Horton S, Fernandes LL, et al
    FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1337.2017.
    >> Share

  93. MENDERES G, Bonazzoli E, Bellone S, Black JD, et al
    SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.2862.2016.
    >> Share

    June 2017
  94. YANG WL, Gentry-Maharaj A, Simmons AR, Ryan A, et al
    Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.0284.2017.
    >> Share

  95. HU Q, Hisamatsu T, Hammerle M, Cho MS, et al
    Role of platelet-derived Tgfbeta1 in the progression of ovarian cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3272.2016.
    >> Share

    March 2017
  96. LEE JM, Peer CJ, Yu M, Amable L, et al
    Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Clin Cancer Res. 2017;23:1397-1406.
    >> Share

  97. WANG C, Armasu SM, Kalli KR, Maurer MJ, et al
    Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.0246.2017.
    >> Share

  98. KRISTELEIT R, Shapiro GI, Burris HA, Oza AM, et al
    A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2796.2016.
    >> Share

  99. APELLANIZ-RUIZ M, Tejero H, Inglada-Perez L, Sanchez-Barroso L, et al
    Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
    Clin Cancer Res. 2017;23:1227-1235.
    >> Share

    February 2017
  100. LHEUREUX S, Lai Z, Dougherty BA, Runswick S, et al
    Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization.
    Clin Cancer Res. 2017 Feb 21. pii: clincanres.2615.2016.
    >> Share

  101. NG C, Zhang Z, Lee SI, Marques HS, et al
    CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.1859.2016.
    >> Share

  102. KOMMOSS S, Winterhoff B, Oberg A, Konecny GE, et al
    Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
    Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016.
    >> Share

    January 2017
  103. SKATES SJ, Greene MH, Buys SS, Mai PL, et al
    Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2750.2015.
    >> Share

  104. ANDERSEN CL, Sikora MJ, Boisen MM, Ma T, et al
    Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016.
    >> Share

    December 2016
  105. KIM H, George E, Ragland RL, Rafail S, et al
    Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2273.2016.
    >> Share

  106. CHATTERJEE J, Dai W, Abd Aziz NH, Teo PY, et al
    Clinical use of programmed cell death-1 (PD-1) and its ligand (PD-L1) expression as discriminatory and predictive markers in ovarian cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2366.2016.
    >> Share

    November 2016
  107. VANDERSTICHELE A, Busschaert P, Smeets D, Landolfo C, et al
    Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses.
    Clin Cancer Res. 2016 Nov 14. pii: clincanres.1078.2016.
    >> Share

  108. MARTINI P, Paracchini L, Caratti G, Mello-Grand M, et al
    lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1402.2016.
    >> Share

    October 2016
  109. BACHMAYR-HEYDA A, Aust S, Auer K, Meier SM, et al
    Integrative Systemic and Local Metabolomics with Impact on Survival in High Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1647.2016.
    >> Share

  110. MONK BJ, Facciabene A, Brady WE, Aghajanian C, et al
    Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1453.2016.
    >> Share

  111. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.0564.2016.
    >> Share

    September 2016
  112. ZHOU J, Alfraidi A, Zhang S, Santiago-O'Farrill J, et al
    A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1562.2016.
    >> Share

  113. FLANAGAN JM, Wilson A, Koo C, Masrour N, et al
    Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.1754.2016.
    >> Share

  114. AU-YEUNG G, Lang F, Azar WJ, Mitchell C, et al
    Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0620.2016.
    >> Share

  115. MARTIGNETTI JA, Chen Y, Camacho C, Silvers TR, et al
    INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1333.2016.
    >> Share

    June 2016
  116. MONTFORT A, Pearce OM, Maniati E, Vincent B, et al
    A strong B cell response is part of the immune landscape in human high-grade serous ovarian metastases.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0081.2016.
    >> Share

  117. BOHM S, Montfort A, Pearce OM, Topping J, et al
    Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2016;22:3025-36.
    >> Share

    July 2015
  118. YANG JY, Werner HM, Li J, Westin SN, et al
    Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
    Clin Cancer Res. 2015 Jul 29. pii: clincanres.0104.2015.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016